Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients

By investing in C2N, Eisai seeks to support efforts to advance blood-based Abeta diagnostics that are accurate and affordable, providing new options for confirming the presence of Abeta.